company background image
RX logo

BioSyent TSXV:RX Stock Report

Last Price

CA$11.55

Market Cap

CA$131.3m

7D

-1.7%

1Y

27.6%

Updated

24 Dec, 2024

Data

Company Financials +

BioSyent Inc.

TSXV:RX Stock Report

Market Cap: CA$131.3m

RX Stock Overview

Acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. More details

RX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends1/6

Rewards

Trading at 3.9% below our estimate of its fair value

Revenue is forecast to grow 12.91% per year

Earnings grew by 14.5% over the past year

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap (CA$131M)


My Notes

Capture your thoughts, links and company narrative

BioSyent Inc. Competitors

Medexus Pharmaceuticals

TSX:MDP

CA$80.1m

Cipher Pharmaceuticals

TSX:CPH

CA$377.2m

Grown Rogue International

CNSX:GRIN

CA$215.6m

Grey Wolf Animal Health

TSXV:WOLF

CA$39.3m

Price History & Performance

Summary of share price highs, lows and changes for BioSyent
Historical stock prices
Current Share PriceCA$11.55
52 Week HighCA$12.13
52 Week LowCA$8.24
Beta0.89
1 Month Change2.67%
3 Month Change5.00%
1 Year Change27.62%
3 Year Change39.16%
5 Year Change89.34%
Change since IPO926.67%

Recent News & Updates

BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

Nov 23
BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Aug 30
BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Recent updates

BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

Nov 23
BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Aug 30
BioSyent's (CVE:RX) Dividend Will Be CA$0.045

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Mar 22
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Feb 09
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14
BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18
BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07
BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17
BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Shareholder Returns

RXCA PharmaceuticalsCA Market
7D-1.7%1.7%-1.4%
1Y27.6%-27.5%15.9%

Return vs Industry: RX exceeded the Canadian Pharmaceuticals industry which returned -27.5% over the past year.

Return vs Market: RX exceeded the Canadian Market which returned 15.9% over the past year.

Price Volatility

Is RX's price volatile compared to industry and market?
RX volatility
RX Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement12.0%
Market Average Movement8.2%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market2.9%

Stable Share Price: RX has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: RX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aRené Goehrumwww.biosyent.com

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.

BioSyent Inc. Fundamentals Summary

How do BioSyent's earnings and revenue compare to its market cap?
RX fundamental statistics
Market capCA$131.32m
Earnings (TTM)CA$7.11m
Revenue (TTM)CA$34.51m

18.5x

P/E Ratio

3.8x

P/S Ratio

Is RX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RX income statement (TTM)
RevenueCA$34.51m
Cost of RevenueCA$7.10m
Gross ProfitCA$27.41m
Other ExpensesCA$20.30m
EarningsCA$7.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.63
Gross Margin79.42%
Net Profit Margin20.60%
Debt/Equity Ratio0%

How did RX perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

29%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:29
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioSyent Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Scott CurtisCantor Fitzgerald Canada Corporation
Tania Armstrong-WhitworthCormark Securities Inc.